How to Import Medicines into Saudi Arabia and the UAE from a UK Supplier

Saudi Arabia and the United Arab Emirates represent two of the fastest-growing pharmaceutical markets in the Middle East. Both countries operate advanced hospital networks, have large expatriate populations requiring diverse medicine formularies, and face ongoing demand for specialty, oncology, and rare disease treatments that are not always manufactured or registered locally.

For hospital procurement teams, government health buyers, and licensed importers across the Gulf, the United Kingdom remains one of the most trusted sources for pharmaceutical supply. UK wholesalers operating under MHRA Wholesale Dealer Authorisation are subject to Good Distribution Practice (GDP) standards, hold medicines in validated temperature-controlled facilities, and can prepare the full documentation package that Gulf regulators require.

This guide covers the regulatory frameworks, documentation requirements, special access pathways, and logistics considerations for importing medicines from the UK into Saudi Arabia and the UAE. It is written for procurement professionals, hospital pharmacists, and supply chain managers who need to understand what the process involves before engaging a UK supplier.

Importing Medicines into Saudi Arabia

The Regulator: Saudi Food and Drug Authority (SFDA)

The Saudi Food and Drug Authority is the sole regulatory body responsible for pharmaceutical affairs in the Kingdom. The SFDA oversees drug registration, manufacturing oversight, import control, post-market surveillance, and the quality standards that apply to every medicine entering the Saudi market. All pharmaceutical imports into Saudi Arabia must pass through SFDA-controlled processes.

For a UK supplier exporting to Saudi Arabia, the critical point is this: a foreign company cannot import medicines directly into the Kingdom. Every pharmaceutical product must be imported through a licensed local agent who is registered with the SFDA and holds a valid Drug Sector import licence. The local agent acts as the regulatory and commercial intermediary, handling the import permit application and in-country distribution.

The Registration Requirement

Before a medicine can be routinely imported into Saudi Arabia, it must hold a marketing authorisation from the SFDA. The registration process requires the foreign manufacturer or marketing authorisation holder to appoint an authorised local agent, who then submits the application through the SFDA's Saudi Drug Registration (SDR) system. The dossier must be in eCTD format and covers the full quality, safety, and efficacy profile of the product.

For products already registered in multiple GCC countries, the GCC Centralised Registration pathway can streamline this process. However, for specialty or rare disease medicines that have limited regional registration, the standard SFDA national procedure or the Special Access Program may be the only viable route.

Special Access Program for Unregistered Medicines

Saudi Arabia operates a Special Access Program (SAP) through the SFDA for situations where a patient requires a medicine that is not registered in the Kingdom. The SAP is designed for urgent or life-threatening medical needs where no locally registered alternative exists. Applications are made on a per-patient or per-institution basis, and the SFDA evaluates each request individually.

The SAP application must include clinical justification from the treating physician, evidence of local unavailability, product documentation from the manufacturer, and details of the quantity required. Quantities are limited per application based on the hospital's capacity and expected patient numbers. The SFDA retains full discretion to approve, modify, or reject any request.

For a UK supplier like Euro Biom, the SAP route is particularly relevant for oncology medicines, enzyme replacement therapies for rare diseases, and specialty biologics that may be widely available in the UK and EU but have not yet completed SFDA registration in Saudi Arabia. We prepare the regulatory documentation package required for SAP submissions, working alongside the hospital's local agent to ensure the application meets SFDA requirements. Read more about our Saudi Arabia supply service.

Documentation for Saudi Import

The documentation standards for Saudi pharmaceutical imports are among the most detailed in the region. A UK supplier exporting to Saudi Arabia should provide the following as standard:

Saudi Healthcare Landscape

Understanding who buys medicines in Saudi Arabia helps a UK supplier prepare the right documentation and service approach. The Kingdom's healthcare system operates across three main pillars.

The Ministry of Health (MOH) runs the largest hospital network with over 280 hospitals and approximately 45,000 beds across 13 provinces. MOH procurement is centralised and follows formal tender processes, often with multi-year contract frameworks. Military healthcare operates separately, with major institutions including Prince Sultan Military Medical City in Riyadh and King Fahd Armed Forces Hospital in Jeddah, both of which procure independently from MOH.

The private sector is expanding rapidly under Saudi Vision 2030, which aims to increase private healthcare expenditure from 25% to 35% of total spending. Major private groups include Dr. Sulaiman Al-Habib Medical Group, Saudi German Hospital, and King Faisal Specialist Hospital and Research Centre, which operates campuses in Riyadh, Jeddah, and Madinah. These private institutions often have more flexibility to procure specialist and unlicensed medicines directly, making them a natural partner for UK exporters focused on non-routine supply.

Importing Medicines into the UAE

The Regulators: EDE, MOHAP, DHA, and DOH

The UAE's pharmaceutical regulatory landscape has historically been more fragmented than Saudi Arabia's, with responsibility shared between federal and emirate-level authorities. The Ministry of Health and Prevention (MOHAP) has traditionally overseen drug registration and import permits at the federal level, while the Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DOH) regulate healthcare services within their respective emirates.

A significant regulatory shift took effect on 2 January 2025 with Federal Decree-Law No. 38 of 2024, which established the Emirates Drug Establishment (EDE) as the centralised regulatory authority for all pharmaceutical matters across the UAE. The EDE now oversees product approvals, surveillance, regulatory compliance, and import requirements, consolidating functions that were previously distributed across multiple bodies. There is a one-year transition period for full compliance with the new framework.

For UK suppliers and their UAE-based import partners, the practical implication is that pharmaceutical import processes are becoming more streamlined under a single federal authority. However, during the transition period, it is important to confirm which body — MOHAP or EDE — is handling a specific product or permit application.

The Import Process

Importing medicines into the UAE follows a two-stage permit process. In the first stage, the local agent submits a pre-import permit application before the shipment leaves the country of origin. This requires a valid marketing authorisation for the product, a commercial invoice, and confirmation that the applicant is the authorised local agent listed on the product's registration. Processing time for the pre-import permit is typically three working days.

The second stage is the shipment clearance application, submitted once the goods are in transit and the air waybill or bill of lading has been issued. EDE inspectors review the documentation and authorise customs clearance. This stage typically takes two working days. The import permit is valid for 60 days from the date of issuance.

Only the local agent named in the product's marketing authorisation can import the product. As with Saudi Arabia, foreign suppliers cannot import directly — they must work through a licensed local pharmaceutical establishment, either a medical warehouse or a marketing office.

Special Pathways for Unregistered Medicines

The UAE permits the import of unregistered medicines under specific circumstances. Hospitals affiliated with the DHA or DOH can apply to import non-registered products for individual patients when the medicine is needed for continuation of treatment, when no registered alternative exists in the UAE market, and when the product holds a marketing authorisation in its country of origin or in an approved reference country such as the UK, EU, or USA.

The quantities permitted are limited to the hospital's capacity and the number of patients requiring the treatment. Non-registered medicines imported through this route cannot be supplied outside the hospital premises — they are for in-hospital use only. For biological products and vaccines, an additional Batch Release Certificate from EDE is required for each batch.

This pathway is particularly relevant for specialty oncology treatments, orphan drugs, and medicines required for patients transferring care from European or US hospitals to UAE facilities. Euro Biom regularly supports hospital pharmacies across the Gulf with named patient and special import supply, providing the documentation package that the importing hospital needs to support their regulatory application.

Dubai Healthcare City and Free Zones

Dubai Healthcare City (DHCC) is the world's largest healthcare free zone, home to two hospitals, over 120 outpatient centres, and more than 4,000 licensed healthcare professionals. The DHCC is regulated by its own independent authority, the Dubai Healthcare City Authority – Regulatory (DHCA-R), which operates alongside federal EDE requirements.

Recent regulatory changes now permit 100% foreign ownership of pharmaceutical distribution companies in both mainland UAE and free zones. This has opened new commercial structures for international pharmaceutical companies looking to establish a direct import and distribution presence in the UAE, rather than operating exclusively through local agents.

Documentation for UAE Import

GCC Centralised Drug Registration

Both Saudi Arabia and the UAE participate in the Gulf Centralised Committee for Drug Registration (GCC-DR), established in 1999 under the Gulf Health Council. The centralised procedure allows a pharmaceutical manufacturer to submit a single registration application that, once approved, provides market access across all six GCC member states: Saudi Arabia, UAE, Bahrain, Kuwait, Oman, and Qatar.

Applications are submitted in eCTD format, and two member states are selected alphabetically to conduct the primary review. All states evaluate the quality, safety, and efficacy data, and approval requires consensus. The centralised procedure also sets a unified CIF price for the product across the region.

The standard timeline for GCC centralised registration is 12 to 18 months. A reliance model introduced in 2020 allows products already approved in at least two GCC countries to apply through a streamlined pathway, reducing the review period significantly.

For UK suppliers, the GCC-DR pathway is relevant when working with manufacturers who want regional market access across the Gulf. However, for urgent or non-routine supply of products not yet centrally registered, the national SFDA or EDE pathways and special access programs remain the practical routes.

Logistics and Cold Chain

Transit Times from Heathrow

London Heathrow is exceptionally well-connected to the Gulf. Direct flights to Riyadh take approximately 6 hours 30 minutes, and to Dubai approximately 7 hours. Jeddah is reachable in just over 6 hours. Multiple daily services operate on all three routes through carriers including British Airways, Emirates, Saudi Arabian Airlines, and Etihad, providing reliable air freight capacity for pharmaceutical shipments.

For standard orders, the total lead time from enquiry to delivery — including documentation preparation, export processing, air freight, and customs clearance — is typically 7 to 14 working days. Emergency orders can be dispatched same day from Euro Biom's Heathrow-adjacent warehouse, with delivery achievable within 48 to 72 hours depending on customs processing at the destination.

Cold Chain in Hot Climates

Temperature management is one of the most critical aspects of pharmaceutical export to the Gulf. Summer temperatures in Saudi Arabia and the UAE routinely exceed 45°C, and ambient temperatures at airport tarmacs and loading bays can be significantly higher. For temperature-sensitive products — including biologics, vaccines, insulins, and certain oncology medicines that require 2°C to 8°C storage — the cold chain must be validated from the UK warehouse door to the receiving hospital's cold room.

The SFDA mandates data logger placement within pharmaceutical shipments, with specifications approved by the authority. Temperature records must demonstrate continuous compliance with the product's stability specifications throughout transit. The UAE imposes similar requirements, with EDE expecting full temperature documentation for import clearance.

Euro Biom works with specialist pharmaceutical logistics providers who operate validated cold chain solutions for Gulf shipments. This includes qualified thermal packaging, phase-change coolants calibrated for Gulf ambient conditions, continuous data logging with tamper-evident seals, and pre-arranged temperature-controlled handling at both departure and arrival airports.

Choosing a UK Supplier for Gulf Export

When evaluating a UK pharmaceutical supplier for export to Saudi Arabia or the UAE, hospital procurement teams and licensed importers should look for several specific capabilities beyond basic wholesale licensing.

First, the supplier must hold an MHRA Wholesale Dealer Authorisation that covers both licensed and unlicensed medicines. This is essential if you need to import specialty products, shortage medicines, or named patient treatments that may not have standard UK marketing authorisations. Second, the supplier should have direct experience preparing documentation for Gulf import — including chamber-certified commercial invoices, CPPs in the correct format, and temperature monitoring records that meet SFDA and EDE requirements.

Third, proximity to Heathrow matters for time-critical supply. A supplier operating from a GDP-compliant warehouse near the airport can dispatch same-day for emergency orders, rather than adding days for internal UK logistics. Fourth, the supplier should understand the Gulf regulatory landscape well enough to advise on which import pathway applies to a specific product — whether standard import, SAP, or hospital special import — and prepare the documentation accordingly.

Euro Biom operates from a warehouse adjacent to Heathrow Airport, holds an MHRA WDA covering licensed and unlicensed medicines, and has supplied hospitals and distributors across the GCC. We prepare the full regulatory documentation package for every shipment and work directly with local agents and hospital pharmacy teams to ensure the import process runs smoothly. Submit an enquiry to discuss your requirements.

Frequently Asked Questions

How do Saudi hospitals import medicines from the UK?

Saudi hospitals import through an authorised local agent registered with the SFDA. The product must hold an SFDA marketing authorisation or qualify for the Special Access Program. The local agent handles the import permit, and the UK supplier provides the CPP, CoA, batch documentation, and temperature records. Euro Biom prepares all export documentation as standard.

What documents does a UK supplier provide for Gulf export?

A UK supplier with MHRA WDA provides a Certificate of Pharmaceutical Product, certificate of analysis, GMP certificate, GDP records, chamber-certified commercial invoice, temperature data logger records, and cold chain validation documentation. For Saudi Arabia, Arabic labelling compliance documentation is also required.

Can unregistered medicines be imported into Saudi Arabia or the UAE?

Yes. Saudi Arabia operates the SFDA Special Access Program for urgent or life-threatening medical needs. The UAE allows affiliated hospitals to import unregistered medicines for specific patients when no local alternative exists and the product is registered in an approved reference country. Both pathways require detailed clinical justification and are quantity-limited.

How long does shipping from the UK to Saudi Arabia or UAE take?

Direct flights from Heathrow to Riyadh take approximately 6.5 hours, and to Dubai approximately 7 hours. Total lead time including documentation and customs clearance is 7 to 14 working days. Emergency orders can achieve delivery within 48 to 72 hours.